Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion type Assertion NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_head.
- NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion wasGeneratedBy ECO_0000203 NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_provenance.
- NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion wasDerivedFrom befree-20140225 NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_provenance.
- NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion SIO_000772 21762356 NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_provenance.
- NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion evidence source_evidence_literature NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_provenance.
- NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_assertion description "[Treatment options for hepatitis delta are limited, with only 25% of patients responding to interferon (IFN)-alfa-based therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924112.RAemowBMgOjYgt0jsgfXJ4LB6Z6ee0LPBk7eLNOMPbVCU130_provenance.